Global Ketamine Treatment Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Ketamine Treatment Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Ketamine is a powerful psychedelic substance with strong dissociative effects used as a general anesthetic in medicine. It has a long history as a party-drug, but more recently ketamine has been found to have therapeutic benefits, specifically when treating treatment-resistant depression, PTSD, and addiction. Ketamine, which was initially used as an anesthetic, is now used in treating depression, anxiety, and post-traumatic stress disorder (PTSD). Ketamine participates in the treatment process in the form of infusions and nasal sprays.

Market Overview:

The latest research study on the global Ketamine Treatment market finds that the global Ketamine Treatment market reached a value of USD 309.31 million in 2022. It’s expected that the market will achieve USD 2681.7 million by 2028, exhibiting a CAGR of 43.33% during the forecast period.

Bring volatility in the short term

COVID-19 has just broken out, and major economies have responded positively by adopting policies such as suspension of work and production, and home isolation, which have had some negative impacts on Ketamine production and ketamine treatment. In the short term, Ketamine Treatment will be suppressed in the short term due to home isolation to prevent and control the epidemic.

Long-term positive impact

During COVID-19, people stay in isolation at home, socializing is blocked, and patients with depression continue to increase. The number of American adults reporting symptoms of stress, anxiety, and depression during the pandemic has increased significantly. The demand for treatment for depression is increasing. At the same time, treatment is a rigid demand, and the demand for Ketamine, which acts as an anesthetic treatment or an analgesic, remains strong. With the gradual improvement of the epidemic, the treatment of other diseases such as surgery has returned to normal, people's demand for hospitals has recovered, and the demand for Ketamine Treatment is also increasing.

There are side effects

Ketamine taken under medical supervision is considered a relatively safe drug. Ketamine is not considered to be a physical addiction, but it may still cause psychological dependence. Patients with high blood pressure, thyroid disease, alcoholism, and aneurysms should use ketamine with caution, because ketamine can increase blood pressure. It has been found that frequent use of high doses can cause neurodegeneration, and frequent use of high doses of ketamine can cause liver and urinary system toxicity. Ketamine can cause increased blood pressure and intracranial pressure, or increased brain pressure. It can also cause loss of appetite, stomach upset, and vomiting. A certain degree of side effects, for certain people, such as coronary artery disease, thyroid disease, chronic alcohol addiction, etc., especially people over 65 years old, ketamine treatment will be limited. Ketamine is also not recommended for pediatric patients younger than 3 months. The existence of side effects has a certain degree of negative impact on the development of the industry.

Prosperity of clinical experimental research

Ketamine's recent breakthrough has cast a huge spotlight on all of the possible medical benefits of the substance. Here are a few current clinical trials: Emergency Ketamine Treatment of Suicidal Ideation; Ketamine Treatment for Pediatric-Refractory Obsessive-Compulsive Disorder (OCD); Open Label Ketamine Treatment for Major Depressive Disorder in Veterans; Ketamine Treatment Effects on Synaptic Plasticity in Depression; Investigation of Antidepressant Efficacy of Oral Ketamine Treatment, etc. With the development of clinical research, the emphasis on Ketamine Treatment will continue to increase, which will also promote the high-level development of the Ketamine Treatment market and bring development opportunities.

Region Overview:

In 2022, the share of the Ketamine Treatment market in United States stood at 76.26%.

Company Overview:

Field Trip Health is one of the major players operating in the Ketamine Treatment market, holding a share of 4.07% in 2022.

Field Trip Health

Field Trip is redefining mental health and well-being through ground-breaking work in psychedelics and psychedelic-enhanced psychotherapy. With Field Trip Health centres opening across North America, and drug development and advanced research on plant-based psychedelics through Field Trip Discovery, Field Trip help people to heal and heighten engagement with the world.

Nue Life Health

Nue Life is a next-gen mental wellness company that believes in the power of psychedelics to catalyze lasting change.

Segmentation Overview:

By type, Infusions segment accounted for the largest share of market in 2022.

Infusions

Ketamine infusions are emerging as one of the most effective treatments for Depression, Anxiety, PTSD and many other psychiatric disorders.
Where other treatments take weeks or months to begin working—and are effective in only about 40% of patients—ketamine infusions take effect almost immediately and alleviate symptoms in upwards of 80% of patients.

Nasal Spray

Ketamine nasal spray is a mist that is compounded by a specialty pharmacy for those who have been approved to use it. Ketamine nasal spray can be used to treat several conditions, such as chronic pain and mood disorders. Ketamine nasal spray is very helpful for the treatment and management of diseases, whether it is mood disorders or chronic neuropathic pain. Nasal ketamine has a fast onset and rapid effect. It is a good rescue medicine for quick pain relief.

Application Overview:

The market's largest segment by application is the segment Depression, with a market share of 50.25% in 2022.

Depression

ketamine has been discovered as an effective treatment for depression, and randomized controlled trials have shown rapid improvement in mood as well as a reduction in suicidality compared to people who receive a placebo or another drug. Ketamine is on the rise as an up-and-coming alternative to antidepressants, specifically treatment-resistant depression.

Anxiety

Anxiety disorders are among the most common mental health concerns. People of all ages suffer from a wide range of debilitating anxiety disorders, including phobias, panic disorder, and other mental health issues involving anxiety as a prominent and distressing symptom. Anxiety disorders are treatable. In many cases, a combination of medication and psychotherapy can help alleviate the associated symptoms.

PTSD

Post-traumatic stress disorder (PTSD), sometimes referred to as post-traumatic stress (PTS), is an incredibly difficult disorder to live with, but research shows that intravenous ketamine for PTSD can be highly effective.
From military veterans to abuse survivors, patients suffering from any type of extreme trauma are at risk of developing changes in brain chemistry. When this occurs, patients commonly experience symptoms of fear, anxiety, and emotional detachment.
Conventional treatment options have included a combination of psychotherapy and oral medications. Now, there's an alternative solution available for PTSD sufferers: intravenous ketamine. PTSD symptoms can dissipate within hours after a ketamine infusion treatment, and lasting benefits can be attained in as little as one to two weeks.

Key Companies in the global Ketamine Treatment market covered in Chapter 3:

Save Minds UK
Novamind
Field Trip Health
Journey Clinical
Numinus Wellness
Nushama
Interpersonal Psychiatry
Ember Health
Mindbloom
Klarisana
Nue Life Health

In Chapter 4 and Chapter 14.2, on the basis of types, the Ketamine Treatment market from 2018 to 2029 is primarily split into:

Infusions
Nasal Spray

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Ketamine Treatment market from 2018 to 2029 covers:

Depression
Anxiety
PTSD
Other

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)